Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
botulinum toxin medication
|
| gptkbp:activeIngredient |
abobotulinumtoxinA
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2009 (US) |
| gptkbp:ATCCode |
M03AX01
|
| gptkbp:chemicalClass |
gptkb:Dragon
|
| gptkbp:contraindication |
hypersensitivity to botulinum toxin
infection at injection site |
| gptkbp:halfLife |
unknown (varies by indication)
|
| https://www.w3.org/2000/01/rdf-schema#label |
Dysport
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Ipsen
|
| gptkbp:mechanismOfAction |
inhibits acetylcholine release at neuromuscular junction
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:relatedTo |
gptkb:Botox
gptkb:Xeomin |
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
headache
muscle weakness injection site pain dysphagia |
| gptkbp:storage |
refrigerated
|
| gptkbp:usedFor |
treatment of cervical dystonia
treatment of glabellar lines treatment of muscle spasticity |
| gptkbp:bfsParent |
gptkb:Botulinum_toxin
|
| gptkbp:bfsLayer |
6
|